Myelofibrosis surgery

	Myelofibrosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myelofibrosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myelofibrosis surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myelofibrosis surgery All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myelofibrosis surgery
CDC on Myelofibrosis surgery
Myelofibrosis surgery in the news
Blogs on Myelofibrosis surgery
Directions to Hospitals Treating Myelofibrosis
Risk calculators and risk factors for Myelofibrosis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]

Overview

Surgery is not the first-line treatment option for patients with myelofibrosis. Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment. The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.

Surgery is not the first-line treatment option for patients with myelofibrosis.
Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment.^[1]^[2]^[3]
It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%.

The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.^[4]

↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
↑ Tefferi A (December 2018). "Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management". Am. J. Hematol. 93 (12): 1551–1560. doi:10.1002/ajh.25230. PMID 30039550.
↑ Pardanani A, Tefferi A (August 2018). "How I treat myelofibrosis after failure of JAK inhibitors". Blood. 132 (5): 492–500. doi:10.1182/blood-2018-02-785923. PMID 29866811.
↑ Cervantes F (2005). "Modern management of myelofibrosis". Br. J. Haematol. 128 (5): 583–92. doi:10.1111/j.1365-2141.2004.05301.x. PMID 15725078. Unknown parameter |month= ignored (help)